Man Cured of HIV via Rare Sibling Stem Cell Transplant

A man in Norway has achieved long-term remission from HIV following a stem cell transplant from his brother, who carries a rare genetic mutation that confers natural resistance to the virus. This case, reported as the first of its kind involving a sibling donor with the CCR5Δ32/Δ32 genotype, marks a significant development in HIV cure research and offers new insights into potential pathways for broader therapeutic strategies.

The patient, referred to in medical reports as the “Oslo Patient,” received an allogeneic hematopoietic stem cell transplant in 2020 to treat a high-risk hematological malignancy. His brother, identified as a human leukocyte antigen (HLA)-matched donor, was later found to be homozygous for the CCR5Δ32 mutation — meaning he inherited two copies of the gene variant, one from each parent, which results in the absence of functional CCR5 co-receptors on immune cells. Since HIV typically uses CCR5 to enter and infect cells, individuals with this mutation are largely resistant to certain strains of the virus.

Following the transplant, the patient’s immune system was effectively replaced by donor-derived cells lacking the CCR5 receptor. Analytical treatment interruption (ATI) was conducted in 2021 under close medical supervision, during which antiretroviral therapy (ART) was stopped to assess whether HIV could rebound. To date, more than three years after stopping ART, the patient has shown no detectable viral rebound, with sensitive assays failing to identify replication-competent HIV in blood or tissue reservoirs.

The case was detailed in a peer-reviewed study published in Nature in April 2024, which confirmed sustained HIV-1 remission without the need for ongoing antiretroviral therapy. Researchers noted that while the patient experienced graft-versus-host disease (GVHD) following the transplant — a known complication where donor immune cells attack the recipient’s tissues — this immune activity may have contributed to the elimination of HIV-infected cells. However, they emphasized that GVHD carries significant risks and is not a viable or ethical strategy for inducing HIV remission outside of life-threatening conditions requiring transplantation.

This outcome builds on the precedent set by the Berlin, London, and Düsseldorf patients, who also achieved HIV remission after stem cell transplants from CCR5Δ32 donors — though in those cases, the donors were unrelated. The Oslo case is notable for demonstrating that a genetically matched sibling can serve as a suitable donor, potentially improving access to matched donors in regions where unrelated donor registries are less diverse.

Experts caution that stem cell transplantation remains a high-risk procedure, typically reserved for patients with life-threatening blood cancers or severe immune disorders. The regimen involves chemotherapy or radiation to destroy the recipient’s bone marrow, followed by infusion of donor stem cells, and carries risks of infection, organ damage, and graft failure. As such, it is not considered a scalable or appropriate intervention for the vast majority of people living with HIV who are otherwise healthy and virally suppressed on ART.

Instead, researchers view such cases as proof-of-concept studies that help illuminate the biological requirements for an HIV cure. The consistent success in individuals receiving CCR5-deficient stem cells reinforces the importance of targeting the CCR5 co-receptor in cure-focused research, including gene-editing approaches like CRISPR-based modifications of hematopoietic stem cells to mimic the CCR5Δ32 mutation.

According to the International AIDS Society’s cure research framework, remission cases like the Oslo Patient contribute to understanding whether long-term control can be achieved without ART and what immune or virological markers might predict sustained remission. Ongoing studies are analyzing the patient’s immune profile, including levels of HIV-specific antibodies, viral DNA, and immune activation, to better define the mechanisms of control.

The patient has remained under longitudinal study by clinicians at Oslo University Hospital and collaborating research institutions. While he reports improved quality of life off ART, medical teams continue to monitor for any signs of viral resurgence, particularly in sanctuary sites such as the central nervous system or lymphoid tissue, where standard blood tests may not detect low-level persistence.

Globally, approximately 39 million people live with HIV, according to the World Health Organization. While antiretroviral therapy has transformed HIV into a manageable chronic condition for many, lifelong treatment adherence, access disparities, and the persistent challenge of viral reservoirs remain barriers to ending the pandemic. Cure-focused research, though still in early stages, aims to develop safe, scalable interventions that could induce sustained remission without the need for daily medication.

As of now, no stem cell transplant-based approach is being pursued as a public health strategy for HIV cure due to its risks, and complexity. Instead, the field is directing efforts toward less invasive methods, including therapeutic vaccines, broadly neutralizing antibodies, and gene and cell therapies that aim to control or eliminate the virus with improved safety profiles.

The Oslo case underscores both the scientific plausibility of an HIV cure and the considerable hurdles that remain before such outcomes can be extended beyond rare, medically necessary transplants. For now, the most effective and accessible tool for managing HIV remains consistent antiretroviral therapy, which, when taken as prescribed, allows people with HIV to live long, healthy lives and prevents sexual transmission of the virus.